دورية أكاديمية
Outcome and prognostic factors in childhood B non-Hodgkin lymphoma from India: Report by the Indian Pediatric Oncology Group (InPOG-NHL-16-01 study).
| العنوان: | Outcome and prognostic factors in childhood B non-Hodgkin lymphoma from India: Report by the Indian Pediatric Oncology Group (InPOG-NHL-16-01 study). |
|---|---|
| المؤلفون: | Rahiman EA; Pediatric Hematology-Oncology Unit and Cytology Department, Post Graduate Institute of Medical Education and Research, Chandigarh, India., Bakhshi S; Rotary Cancer Institute, All India Institute of Medical Sciences, New Delhi, India., Deepam Pushpam; Rotary Cancer Institute, All India Institute of Medical Sciences, New Delhi, India., Ramamoorthy J; Adyar Cancer Institute, Chennai, India., Das A; Tata Medical Center, Kolkata, India., Ghara N; Tata Medical Center, Kolkata, India., Kalra M; Apollo Hospital, New Delhi, India., Kapoor G; Rajiv Gandhi Cancer Institute, New Delhi, India., Meena JP; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India., Siddaigarhi S; Rainbow Children's Hospital, Hyderabad, India., Thulkar S; Rotary Cancer Institute, All India Institute of Medical Sciences, New Delhi, India., Sharma MC; Rotary Cancer Institute, All India Institute of Medical Sciences, New Delhi, India., Srinivasan R; Pediatric Hematology-Oncology Unit and Cytology Department, Post Graduate Institute of Medical Education and Research, Chandigarh, India., Trehan A; Pediatric Hematology-Oncology Unit and Cytology Department, Post Graduate Institute of Medical Education and Research, Chandigarh, India. |
| المصدر: | Pediatric hematology and oncology [Pediatr Hematol Oncol] 2022 Aug; Vol. 39 (5), pp. 391-405. Date of Electronic Publication: 2022 Jan 03. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8700164 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0669 (Electronic) Linking ISSN: 08880018 NLM ISO Abbreviation: Pediatr Hematol Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2006- : London : Informa Healthcare Original Publication: Washington, DC : Hemisphere Pub. Corp., c1986- |
| مواضيع طبية MeSH: | Burkitt Lymphoma*/drug therapy , Lymphoma, Large B-Cell, Diffuse*/drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Child ; Disease-Free Survival ; Humans ; Prognosis ; Recurrence ; Retrospective Studies ; Treatment Outcome |
| مستخلص: | The literature on B-non-Hodgkin lymphoma (NHL) in India is restricted to individual hospital data. The study aimed to evaluate the epidemiology and outcome of B-NHL in our country. One hundred and ninety-one patients of B-NHL from 10 centers diagnosed between 2013 and 2016 were analyzed retrospectively. B/T lymphoblastic lymphoma and patients with inadequate data were excluded. The median age was 88 months (IQR: 56, 144) with an M:F ratio of 5.6:1. Undernourishment and stunting were seen in 36.5% and 22%. Primary site was abdomen in 66.5%. Hypoalbuminemia was noted in 82/170 (48.2%). Histological subtypes: Burkitt lymphoma (BL): 69.6%, Burkitt-like: 10.4%, and diffuse large B cell lymphoma (DLBCL): 13.6%, unclassified and others (6.4%). Stage distribution: I/II, 33 (17.3%), III, 114 (59.7%), and IV, 44 (23%). One-eighty-six patients took treatment. Protocols used were LMB and BFM in 160/186 (86%). At a median follow-up of 21.34 (IQR: 4.34, 36.57) months, the disease-free-survival (DFS) was 74.4% and event-free-survival (EFS) was 60.7%. Treatment-related mortality (TRM), relapse/progression and abandonment were 14.3%, 14.5%, and 8.4%, respectively. Bone marrow positivity, stage IV disease, and lactate dehydrogenase (LDH) > 2,000 U/l predicted inferior EFS. Stage IV disease, LDH > 2,000 U/l, bone marrow positivity, tumor lysis syndrome and low albumin predicted TRM; LDH retained significance on multivariate analysis for EFS and TRM [OR: 4.54, 95% CI: 1.14-20, p 0.03; OR 20, 95%CI: 1.69-250, p 0.017]. BL was the main histological subtype. High TRM and relapse/progression are hampering survival. An LDH > 2,000 U/l was adversely prognostic. These data demonstrate a need to develop a national protocol that balances toxicity and potential for cure. |
| فهرسة مساهمة: | Keywords: Child; India; lactate dehydrogenase; multicenter study; survival; toxicity; treatment-related mortality |
| تواريخ الأحداث: | Date Created: 20220103 Date Completed: 20220815 Latest Revision: 20220815 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1080/08880018.2021.2002485 |
| PMID: | 34978257 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1521-0669 |
|---|---|
| DOI: | 10.1080/08880018.2021.2002485 |